Sorafenib tosylate

‌Sorafenib Tosylate | Anticancer Tyrosine Kinase Inhibitor, 99% Purity, USP/EP Certified‌

✧ ‌Product Overview‌

Sorafenib Tosylate is a ‌multitarget tyrosine kinase inhibitor‌ approved for advanced ‌hepatocellular carcinoma (HCC)‌, ‌renal cell carcinoma (RCC)‌, and ‌thyroid cancer‌. It inhibits ‌VEGFR, PDGFR, and RAF kinases‌, blocking tumor angiogenesis and proliferation. As the active ingredient in Nexavar®, it is widely used in ‌first-line therapy‌ for unresectable liver and kidney cancers.

✧ ‌Key Advantages‌

🔹 ‌High Potency & Selectivity‌

• Targets ‌VEGFR-2 (IC₅₀: 90 nM)‌ and ‌RAF-1 (IC₅₀: 6 nM)‌ with precision‌45.

• ‌>99% purity‌ (HPLC/UV validated) for pharmaceutical-grade quality‌26.

🔹 ‌Broad-Spectrum Antitumor Activity‌

• Dual action: suppresses tumor growth ‌and‌ angiogenesis‌45.

• Effective against ‌BRAF-mutated cancers‌ (e.g., melanoma)‌4.

🔹 ‌Oral Bioavailability‌

• Single-dose convenience with ‌prolonged therapeutic effects‌‌5.

✧ ‌Applications‌

• ‌Hepatocellular Carcinoma (HCC)‌: First-line treatment for advanced stages‌13.

• ‌Renal Cell Carcinoma (RCC)‌: Standard therapy for metastatic cases‌13.

• ‌Thyroid Cancer‌: Approved for radioactive iodine-resistant tumors‌35.

• ‌Clinical Research‌: Investigated for NSCLC and melanoma‌45.

✧ ‌Quality Certifications‌

• Complies with ‌USP/EP/BP monographs‌‌23.

• Batch-specific ‌COA‌ with ‌HPLC, NMR, and residual solvent analysis‌‌67.

• Stability tested under ‌ICH Q1A guidelines‌ (24-month shelf life)‌67.

✧ ‌Market Trends‌

The global oncology kinase inhibitor market is projected to grow at ‌CAGR 8.5% (2025–2030)‌, driven by rising HCC/RCC prevalence‌35. Sorafenib Tosylate remains a cornerstone therapy, with ‌$1.2 billion annual sales‌ in 2024, supported by its proven efficacy and expanding off-label applications‌35.